Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pleural Effusion 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lung Neoplasms 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Cdc25C phosphatase (211-221) × Clear all
NCT04953962 2023-08-15

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

CanBas Co. Ltd.

Phase 2 Completed
36 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00700336 2021-07-20

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

CanBas Co. Ltd.

Phase 1/2 Completed
69 enrolled 9 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03113188 2021-03-10

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

CanBas Co. Ltd.

Phase 1 Completed
47 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00942825 2017-05-24

CBP08-02

CanBas Co. Ltd.

Phase 2 Completed
195 enrolled 8 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion

NCT00551512 2017-03-14

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

CanBas Co. Ltd.

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡